Prosecution Insights
Last updated: April 19, 2026
Application No. 18/537,700

INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS

Non-Final OA §DP
Filed
Dec 12, 2023
Examiner
LEESER, ERICH A
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanford Burnham Prebys Medical Discovery Institute
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
95%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allow Rate
773 granted / 948 resolved
+21.5% vs TC avg
Moderate +14% lift
Without
With
+13.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
15 currently pending
Career history
963
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
12.7%
-27.3% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
38.4%
-1.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 948 resolved cases

Office Action

§DP
DETAILED ACTION This action is in response to Applicant’s submission dated August 26, 2025, in which Applicant elected a species without traverse. Once this species was not found in the prior art, the full scope of the invention was searched in the art. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The non-statutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b). Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 25-26, 28, 33-34, 36, 43, 51-52, 59-60, and 68-73 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-16 and 19-25 of Fisher, et al., United States Patent No. 11,891,399. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter embraced in the instant claims is also embraced in United States Patent No. 11,891,399. The claims of the reference and the instant claims are obvious variants of one another because there is substantial overlap between instant L1, z1, L2, Z, R1, R2, R3, R4, R1A to R4B, X to X4, n1, n2, m1, m2, v1, v2, and z1, and their corresponding positions in the reference when R2 of the reference is a ring (cycloalkyl, heterocycloalkyl, aryl, or heteroraryl). Claims 25-26, 28-30, 33-36, 43, 51-52, 59-60, and 68-73 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-25 and 29-50 of Fisher, et al., United States Patent No. 11,008,325. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter embraced in the instant claims is also embraced in United States Patent No. 11,008,325. The claims of the reference and the instant claims are obvious variants of one another because there is substantial overlap between instant L1, z1, L2, Z, R1, R2, R3, R4, R1A to R4B, X to X4, n1, n2, m1, m2, v1, v2, and z1, and their corresponding positions in the reference. Conclusion Any inquiry concerning this communication or earlier communications from the Examiner should be directed to ERICH A LEESER whose telephone number is (571) 272-9932. The Examiner can normally be reached Monday through Friday from 10-6 PST, M-F. PST. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Mr. James Alstrum-Acevedo can be reached at (571) 272-5548. The fax number for the organization where this application is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) toll-free at 866-217-9197. If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICH A LEESER/Primary Examiner, Art Unit 1622 United States Patent and Trademark Office Tel. No.: (571) 272-9932
Read full office action

Prosecution Timeline

Dec 12, 2023
Application Filed
Oct 22, 2025
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590082
FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12589099
ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY
2y 5m to grant Granted Mar 31, 2026
Patent 12590106
SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS
2y 5m to grant Granted Mar 31, 2026
Patent 12570622
THERAPEUTIC COMPOUNDS
2y 5m to grant Granted Mar 10, 2026
Patent 12565518
HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
95%
With Interview (+13.5%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 948 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month